| 发明名称 |
TYPE 1 INTERFERON DIAGNOSTIC |
| 摘要 |
The present disclosure encompasses type-I IFN and IFNα-induced PD marker expression profiles, kits, and methods for identifying such IFNα-induced PD marker expression profiles. The type-I IFN and IFNα-induced PD marker expression profiles may also be used in, for example, methods of treating patients having a type-I IFN or IFNα-mediated disorder, methods of monitoring disease progression of patients receiving treatment with a therapeutic agent that modulates type 1 interferon activity, identifying patients as candidates to receive a therapeutic that binds to and neutralizes IFNα activity, and in diagnosing or providing a prognosis to patients having IFNα-induced disorders. |
| 申请公布号 |
US2015191788(A1) |
申请公布日期 |
2015.07.09 |
| 申请号 |
US201514662134 |
申请日期 |
2015.03.18 |
| 申请人 |
MEDLMMUNE, LLC |
发明人 |
HIGGS BRANDON;ZHU WEI;MOREHOUSE CHRIS;WHITE BARBARA;JALLAL BAHIJA;YAO YIHONG |
| 分类号 |
C12Q1/68 |
主分类号 |
C12Q1/68 |
| 代理机构 |
|
代理人 |
|
| 主权项 |
1. A method of identifying a subject suitable for treatment with a therapeutic agent that modulates type 1 interferon activity comprising detecting increased mRNA of at least four of IFI27, IFI44, IFI44L, IFI6, and RSAD2 in a sample of the subject, wherein an increase in mRNA of at least about four fold indicates a subject suitable for treatment with the agent. |
| 地址 |
GAITHERSBURG MD US |
